CMAAO Coronavirus Facts and Myth Buster: Co-Infection

With input from Dr Monica Vasudev

1088:    Flu, COVID-19 or Both? Dont Ignore Co-Infection

  • When a patient presents with acute respiratory symptoms this winter, the CDC says that clinicians should consider three options: influenza, COVID-19, or co-infection.
  • Co-infection with both influenza and COVID-19 has been documented in case reports as well as case series.
  • The differentiating feature is loss of smell and loss of taste, which has not been reported with influenza virus infection.
  • Timothy Uyeki, MD, of the CDC, discussed the largest case series of patients with influenza and SARS-CoV-2 co-infection which included 93 adult patients hospitalized with COVID-19 in Wuhan, China, where 49.5% had serologically diagnosed influenza infection.
  • Co-infection, or even distinguishing SARS-CoV-2 from influenza, is of particular significance because of the implications of treatment. For instance, dexamethasone is recommended for severe COVID-19 infection in hospitalized patients; however, corticosteroids tend to prolong viral replication in influenza.
  • Testing therefore becomes vital when it comes to distinguishing the viruses.
  • There are different types of multiplex assays that have received FDA emergency use authorization (EUA). These include multiplex nucleic acid detection assays that can identify both influenza A and B viruses and SARS-CoV-2 simultaneously in respiratory samples. Turnaround times for results within the lab vary from 20 minutes to 8 hours.
  • Patients having a high risk for influenza complications, and who may benefit from early antiviral treatment, depict those at higher risk for SARS-CoV-2: Adults >65; Pregnant/postpartum women; People with underlying medical conditions, such as pulmonary, cardiac, and neurologic problems, and those who are immunosuppressed or have a body mass index >40; and Residents of nursing homes/chronic care facilities.
  • Children aged 18 and below receiving long-term aspirin therapy, as well as children below age 2, may also be considered for early antiviral treatment.

 

Dr KK Aggarwal

President CMAAO, HCFI and Past National President IMA

Be the first to comment

Leave a Reply

Your email address will not be published.


*